Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
235.72(c) 230.71(c) 231.1(c) 228.97(c) 227.98(c) Last
2 059 919 2 749 811 1 950 786 1 978 691 2 166 145 Volume
+0.30% -2.13% +0.17% -0.92% -0.43% Change
More quotes
Financials (USD)
Sales 2020 25 378 M - -
Net income 2020 6 845 M - -
Net Debt 2020 19 613 M - -
P/E ratio 2020 19,9x
Yield 2020 2,78%
Sales 2021 26 481 M - -
Net income 2021 8 091 M - -
Net Debt 2021 18 480 M - -
P/E ratio 2021 16,6x
Yield 2021 2,97%
Capitalization 134 B 134 B -
EV / Sales 2020 6,03x
EV / Sales 2021 5,74x
Nbr of Employees 23 400
Free-Float 99,8%
More Financials
Company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Notations Surperformance© of Amgen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AMGEN INC.
10/21AMGEN : Announces 2020 Fourth Quarter Dividend
PR
10/19AMGEN : Applying the Power of Omics to R&D
PU
10/19AMGEN : How Some Amgen Scientists, Researchers Navigate COVID-19 Complacency
PU
10/18Tax Increase for Corporations Looks More Likely as Election Nears
DJ
10/09AMGEN : Cytokinetics And Servier Announce Topline Results From GALACTIC-HF, A Ph..
AQ
10/09Antibody Drugs Touted by Trump Could Be Next to Get Authorized for Covid-19
DJ
10/08Eli Lilly in deal to supply COVID-19 drugs to low-income countries
RE
10/08Amgen Down Nearly 7% After Drug Study Misses Secondary Endpoint -- Data Talk
DJ
10/08CYTOKINETICS INCORPORATED : Shares Fall More Than 40% After Study Miss
DJ
10/08AMGEN : Cytokinetics Heart-Failure Study Hits Main Endpoint, Misses Secondary
DJ
10/08AMGEN : Cytokinetics and Servier Announce Topline Results From GALACTIC-HF, a Ph..
AQ
10/08Eli Lilly in deal to supply COVID-19 drugs to low-income countries
RE
10/07Eli Lilly Asks FDA to Authorize Covid-19 Antibody Drug--2nd Update
DJ
10/07Eli Lilly Asks FDA to Authorize Covid-19 Antibody Drug--Update
DJ
10/06AMGEN : Undruggable Targets Meet Their Match in New Amgen Science Cartoon
PU
More news
News in other languages on AMGEN INC.
10/09Aktien New York: Vor freundlichem Abschluss einer starken Woche
10/09Aktien New York: Vor freundlichem Abschluss einer starken Woche
10/08Aktien New York Schluss: Hoffnung auf Konjunkturhilfe treibt weiter an
10/08Aktien New York: Anleger setzen auf Konjunkturhilfen - IBM triumphiert im Dow
10/08AKTIE IM FOKUS : Amgen brechen ein nach enttäuschenden Studiendaten
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 258,16 $
Last Close Price 227,98 $
Spread / Highest target 35,1%
Spread / Average Target 13,2%
Spread / Lowest Target -18,9%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-5.43%134 106
JOHNSON & JOHNSON-1.33%378 942
ROCHE HOLDING AG-4.73%283 006
PFIZER INC.-4.31%206 049
MERCK & CO., INC.-14.16%197 458
NOVARTIS AG-16.89%186 106